Severe skin rash in two consecutive patients treated with 2-chlorodeoxyadenosine for hairy cell leukaemia at a single institution.
Although hairy cell leukaemia was first described 40 years ago, it is only in the last decade that newer therapeutic agents have enabled effective treatment. The purine nucleoside analogue, 2-chlorodeoxyadenosine (2-CdA) is currently considered as first-line therapy with a very high rate of complete remission. Although adverse events with 2-CdA are increasingly recognized, severe cutaneous reactions have been reported rarely. We describe two consecutive patients treated with 2-CdA for hairy cell leukaemia who both suffered extremely severe cutaneous reactions, one of which was life-threatening.
Grey
M R
MR
Haematology/Oncology Unit, Blackpool Victoria Hospital NHS Trust, Blackpool, UK.
Flanagan
N G
NG
Kelsey
P R
PR
D000208:Acute Disease; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D017338:Cladribine / Q000008:administration & dosage / Q000009:adverse effects*; D004211:Disseminated Intravascular Coagulation / Q000139:chemically induced / Q000628:therapy; D004890:Erythema / Q000139:chemically induced* / Q000628:therapy; D004892:Erythema Multiforme / Q000139:chemically induced / Q000628:therapy; D006801:Humans; D007943:Leukemia, Hairy Cell / Q000150:complications* / Q000188:drug therapy; D008297:Male
D000900:Anti-Bacterial Agents; D017338:Cladribine